Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Insulin Lispro and Insulin Human for Managing Blood Sugar After Meals in Type 1 Diabetes Patients with Different Gastric Emptying Rates

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of different fast-acting insulin treatments for individuals with Type 1 Diabetes. The insulins being tested include Lyumjev, Humalog, and Huminsulin. These insulins are designed to help manage blood sugar levels after meals. The main goal of the study is to find the best insulin option that can help control blood sugar levels effectively after eating, while also considering how quickly the stomach empties food into the intestines.

Participants in the study will receive one of the insulin treatments through a subcutaneous injection, which means the insulin is injected under the skin. The study will observe how these insulins affect blood sugar levels after meals and how they might influence the production of certain substances in the body that can cause stress to cells, known as reactive oxygen species. The study will also look at how the speed of stomach emptying affects blood sugar control with these insulins.

The trial will take place over a period of time, during which participants will be monitored to see how their blood sugar levels respond to the different insulin treatments. The study aims to provide insights into which insulin works best for people with Type 1 Diabetes, depending on how quickly their stomachs empty food. This information could help improve the management of blood sugar levels and reduce the risk of complications associated with high blood sugar.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on criteria such as having type 1 diabetes, an HbA1c level between 6.0% and 8.0%, being in generally good health, aged between 18 and 80 years, and having a body mass index (BMI) between 18.5 and 35 kg/m².

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate health status and establish baseline measurements. This includes measuring blood glucose levels and assessing gastric emptying rates.

  3. Step 3

    Medication administration

    Participants receive one of the following insulin preparations: Lyumjev 100 units/mL, Humalog 100 units/mL, or Huminsulin Normal 100 units/mL. These are administered via subcutaneous injection before meals.

    The dosage and frequency are determined based on individual needs and the specific insulin preparation used.

  4. Step 4

    Monitoring and data collection

    Regular monitoring of blood glucose levels is conducted to assess the effects of the insulin on post-meal blood sugar levels.

    Data on the formation of reactive oxygen species and other metabolic parameters are collected to evaluate the impact of the insulin.

  5. Step 5

    Evaluation of results

    The primary goal is to optimize post-meal blood glucose levels by selecting the most suitable rapid-acting insulin based on gastric emptying speed.

    Secondary evaluations include comparing the effects of different insulins on oxidative stress markers and other metabolic responses.

  6. Step 6

    Completion of the study

    The study is expected to conclude by November 30, 2025. Final assessments are conducted to evaluate the overall outcomes and effectiveness of the insulin treatments.

Who can join the trial?

5 criteria

  • You must have Type 1 Diabetes.
  • Your HbA1c level, which is a measure of your average blood sugar over the past 2 to 3 months, should be between 6.0% (42 mmol/l) and 8.0% (64 mmol/l).
  • You should be in generally good overall health.
  • Your age must be between 18 and 80 years old.
  • Your Body Mass Index (BMI), which is a measure of body fat based on height and weight, should be between 18.5 and 35 kg/m².

Who cannot join the trial?

4 criteria

  • Individuals who do not have Type 1 Diabetes cannot participate.
  • Participants must be within the specified age range, which is not detailed here.
  • Both males and females are eligible, so gender is not a reason for exclusion.
  • Individuals considered part of a vulnerable population are not excluded, meaning those who might need special protection are not automatically disqualified.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Insulin Lispro

    is a fast-acting insulin used to control blood sugar levels in people with type 1 diabetes. It is typically taken before meals to help manage the rise in blood sugar that occurs after eating. In this trial, it is being studied to see how it affects blood sugar levels and oxidative stress in people with different rates of gastric emptying.

  • Insulin Aspart

    is another rapid-acting insulin that helps manage blood sugar spikes after meals. It works quickly to lower blood sugar levels and is being evaluated in this study to determine its effectiveness in individuals with varying gastric emptying speeds.

  • Insulin Glulisine

    is also a fast-acting insulin used to control post-meal blood sugar levels. This trial is examining its role in optimizing blood sugar control and reducing oxidative stress in people with type 1 diabetes, depending on how quickly their stomach empties food.

What is already known about the treatment

Insulin Lispro – This medication is administered via subcutaneous injection and is used to manage blood sugar levels in individuals with Type 1 Diabetes. It is a rapid-acting insulin that helps control blood glucose levels after meals. Insulin Lispro works by mimicking the body's natural insulin, facilitating the uptake of glucose into cells, and reducing glucose production in the liver. It is classified as a rapid-acting insulin analog and is well-documented in medical literature for its effectiveness in managing postprandial blood glucose levels.

Investigated diseases

Type 1 Diabetes – Type 1 Diabetes is a chronic condition where the pancreas produces little or no insulin, a hormone needed to allow sugar (glucose) to enter cells to produce energy. It typically appears in adolescence or early adulthood, but it can develop at any age. The disease progresses as the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. This leads to high blood sugar levels, which can cause symptoms like increased thirst, frequent urination, hunger, fatigue, and blurred vision. Over time, if not managed properly, it can lead to complications affecting the heart, nerves, eyes, and kidneys. The management of Type 1 Diabetes involves monitoring blood sugar levels and administering insulin to maintain normal glucose levels.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-509217-37-00Protocol codeKKB_2023_FActIn-T1DMEstimated enrolment20 patientsSponsorKatholisches Klinikum Bochum gGmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).